SCHEMBL5607415

SCHEMBL5607415

Cc1ccc(Oc2ccc(-c3nnn[nH]3)cc2)c(O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.40
CHEK2 O96017 3/20 0.38
MEN1 O00255 3/20 0.36
RAB9A P51151 3/20 0.36
KMT2A Q03164 3/20 0.36
CASP3 P42574 2/20 0.36
SENP8 Q96LD8 2/20 0.36
SENP7 Q9BQF6 2/20 0.36
SENP6 Q9GZR1 2/20 0.36
JAK2 O60674 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
NPC1 O15118 2/20 0.35
XDH P47989 1/20 0.34
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18383408 0.81 CYP2C9 (0.45) CHEK2MEN1RAB9AKMT2ALMNA
SCHEMBL5607912 0.78 KMT2A (0.38) MEN1RAB9AKMT2ACASP3SENP8
SCHEMBL5607393 0.76 XDH (0.51) KMT2AXDHGAACYP2C9
SCHEMBL16309243 0.76 AR (0.54) ARMEN1KMT2ALMNAMAPT
SCHEMBL184092 0.74 DCUN1D1 (0.44) MEN1RAB9AKMT2ACASP3SENP7
SCHEMBL5607290 0.73 ALDH1A1 (0.52) ARCHEK2XDH
SCHEMBL14556361 0.73 NOX1 (0.40) PTPN1
SCHEMBL6893249 0.73 DCUN1D1 (0.43) MEN1RAB9AKMT2ACASP3SENP7
Hydrochloric Acid SCHEMBL28614073 0.73 DCUN1D1 (0.43) MEN1RAB9AKMT2ACASP3SENP7
SCHEMBL5613924 0.72 KMT2A (0.43) MEN1RAB9AKMT2ACASP3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP claimed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US claimed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO claimed
EP-1838300-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS Emergent Product Development Gaithersburg Inc. (US) 2007-10-03 EP disclosed
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. 2006-09-21 US disclosed
WO-2006071471-A2 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211697-A1 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents TYR, NFE2L2, CYP1A1 AR 1336/4885CHEK2 2741/4885MEN1 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.